SAN DIEGO--(BUSINESS WIRE)--Minnow Medical, a developer of innovative products to treat artery disease, today announced it has received the CE Mark clearing its disposable catheter for marketing in the European Union. The catheter utilizes the Company’s proprietary Guided Reshaping Technology (GRT™) to treat peripheral artery disease (PAD). Minnow’s GRT treats artery disease by precise delivery of controlled radio frequency (RF) energy to open diseased arteries. The RF energy is delivered through electrodes on the surface of a specially designed disposable angioplasty balloon catheter.
“We are very pleased to receive the CE Mark, and look forward to continuing to educate the European market about the advantages of our technology to treat PAD,” said Tom Steinke, president and chief executive officer of Minnow Medical. “Our catheter system is easy to use, and involves a shorter, less complex procedure compared with angioplasty, atherectomy or laser treatments. Furthermore, we believe our technology represents a breakthrough that could dramatically reduce the use of stents in peripheral procedures.”
Minnow is currently conducting clinical trials in Europe with a first-generation version of its catheter system.
Peripheral artery disease affects approximately 27 million people in North America and Europe, and many of the current treatments provide only limited or short-term benefit. The PAD device treatment market is estimated at $1.2 billion per year in the United States alone.
About Minnow Medical, Inc.
Minnow Medical, Inc. headquartered in San Diego, California is a developmental stage company founded in 2003. Minnow Medical is establishing its first products in the treatment of peripheral arterial disease. Minnow Medical’s extensive experience in cardiovascular biology, radiofrequency energy, and tissue biology, combined with scientific experience in atherosclerosis, has resulted in the development of an advanced technology in the treatment of artery disease.
